THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

For Cubist, a tough sell

Despite robust US sales of its antibiotic Cubicin, the Lexington biotech finds global success is difficult to achieve

Cubist won Food and Drug Administration approval in 2003 to market Cubicin, after several years of research and development. The drug is mainly used to fight skin infections caused by certain bacteria. Cubist won Food and Drug Administration approval in 2003 to market Cubicin, after several years of research and development. The drug is mainly used to fight skin infections caused by certain bacteria. (PHOTOS BY Jonathan Wiggs/Globe Staff)
By Todd Wallack
Globe Staff / August 18, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Since Cubist Pharmaceuticals Inc. launched its first drug five years ago - an antibiotic called Cubicin - sales have skyrocketed. (Full article: 848 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass